AUTHORS
Chloé Caudrelier, Paul Palko2, Anaïs Schavgoulidze Jr3, Noemie Bigot I4, Aurore Perrot Sr, MD5, Caroline Jacquet, MD6, Murielle Roussel, MD, PhD7, Cyrille Hulin, MD8, Gaelle Laboure, MD9, Mohamad Mohty, MD, PhD10, Francois Lifermann11, Karim Belhadj Merzoug, MD12, Frederique Orsini Piocelle, MD13, Xavier Leleu Sr, MD, PhD14, Thierry Facon, MD15, Jerome Lambert, PhD16, Jill Corre Sr, PharmD17, Salomon Manier, MD, PhD18
AFFILIATIONS
1 Lille University Hospital, Lille, France, PERSTIM lab, INSERM UMR-S1277, Lille University, Lille, France
2 Saint-Louis Hospital - APHP, Paris, France
3 IUCT Oncopole, Toulouse, France
4 Saint-Louis Hospital - APHP, Paris, France
5 IUCT Oncopole, Toulouse, France
6 Nancy University Hospital, Nancy, France
7 Limoges University Hospital, Limoges, France
8 Bordeaux University Hospital, Bordeaux, France
9 Centre Hospitalier de Libourne, Libourne, France
10 Saint-Antoine Hospital, APHP, Paris, France
11 Centre Hospitalier de Dax-Côte d'Argent, Dax, France
12 Créteil University Hospital, APHP, Créteil, France
13 Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France
14 Poitiers University Hospital, Poitiers, France
15 Lille University Hospital, Lille, France
16 Saint-Louis Hospital - APHP, Paris, France
17 IUCT Oncopole, Toulouse, France
18 Lille University Hospital, Lille, France, PERSTIM lab, INSERM UMR-S1277, Lille University, Lille, France
ABSTRACT
Introduction. Frontline daratumumab, lenalidomide, and dexamethasone (DRd) is a standard of care for transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM). Although the MAIA trial demonstrated outstanding efficacy (median PFS of 61.9 months and median OS of 90 months), long-term outcomes in routine clinical practice remain limited. We evaluated DRd in a large French multicenter real-world cohort.
Methods. We analyzed 992 consecutive TIE patients with NDMM treated with frontline DRd between January 2021 and December 2024, in French IFM centers. Clinical and genomic data were obtained from an institutional review board–approved myeloma database. Cytogenetic risk was classified according to the updated IMWG/IMS definition. Overall and progression-free survival were estimated by Kaplan-Meier with 95% confidence intervals. Standardized mortality ratios (SMR) were calculated using age-, sex-, and calendar year-matched French population mortality data.
Results. The median age was 74.5 years (34-92); 465 (47%) patients were ≥ 75 years and 155 (16%) were > 80 years. Overall, 444 (45%) were female. According to the International Staging System (ISS), 216 (26%) patients had stage I disease, 367 (45%) stage II, and 238 (29%) stage III, among 821 evaluable patients. All patients had cytogenetic assessment by next-generation sequencing (NGS); 799 (80.5%) had standard-risk (SR) features and 193 (19.5%) had high-risk (HR) features, per the new IMWG/IMS consensus. With a median follow-up of 33.5 months, median PFS was not reached and median OS was also not reached. The 3- and 4-year PFS rates were 68.3% [64.9-71.9] and 59.4% [55.2-63.9], respectively while 3- and 4-year OS rates were 86.6% [84.1-89.2] and 81.9% [78.5-85.4], respectively. Subgroup analyses showed 3-year PFS rates of 57.5%, 69.9%, 70.5%, and 59.7% among patients aged <65, 65-69, 70-80, and > 80 years, respectively. Median PFS was not reached in patients with SR cytogenetics and was 33.3 months in patients with HR cytogenetics (p<0.0001). Applying age-, sex-, and calendar year-specific mortality rates from the general French population (INSEE database) to the cohort, we compared observed and expected deaths. The overall standardized mortality ratio (SMR) was 1.5 (95%CI 1.3 to 1.8, p<0.0001). Notably, patients aged >80 years no longer exhibited excess mortality (SMR 1.2; 95% CI, 0.8–1.7, p=0.27), whereas younger patients (≤80 years old) remained at increased risk of death (SMR 1.7; 95% CI, 1.4–2.1, p<0.0001).
Conclusion. This large multicenter real-world study confirms that frontline DRd achieves outcomes comparable to those observed in the pivotal MAIA trial despite a less selected patient population. Remarkably, patients aged >80 years achieved survival comparable to that of the general French population, highlighting the substantial clinical benefit of DRd in very elderly patients.
DISCLOSURES
Chloé Caudrelier: No relevant conflicts of interest to declare.